Magrey M, Yi E, Wolin D, Price M, Chirila C, Davenport E, Park Y. Understanding barriers in the pathway to diagnosis of ankylosing spondylitis: results from a US survey of 1690 physicians from 10 specialties. ACR Open Rheumatol. 2020 Oct;2(10):616-26. doi: 10.1002/acr2.11179
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Launois R, Le Moine J, Uzzan B, Fiestas Navarette LI, Benamouzig R. Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical andguaiac-based fecal occult blood tests for colorectal cancer screening. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):978-89. doi: 10.1097/MEG.0000000000000160
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Roberts J, Price J, Nelson LM, Burchinal M, Hennon E, Barnes B. Receptive vocabulary, expressive vocabulary, and speech production of boys with fragile X syndrome in comparison to boys with Down syndrome. Am J Ment Retard. 2007 May 1;112:177-93.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.